Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
KalVista Pharmaceuticals, Inc. (KALV) had Stock-Based Compensation of $8.65M for the most recently reported fiscal quarter, ending 2025-01-31.
| Income Statement Financials | |
-- |
|
$-48.51M |
|
-- |
|
-- |
|
$42.94M |
|
$-42.94M |
|
$-1.32M |
|
$-44.26M |
|
$-44.26M |
|
$-48.51M |
|
$-48.51M |
|
$-48.51M |
|
$-48.51M |
|
$-42.94M |
|
$-42.71M |
|
52.64M |
|
52.64M |
|
$-0.92 |
|
$-0.92 |
|
| Balance Sheet Financials | |
$267.36M |
|
$1.81M |
|
$8.63M |
|
$275.99M |
|
$25.61M |
|
-- |
|
$105.25M |
|
$130.87M |
|
$145.13M |
|
$145.13M |
|
$145.13M |
|
49.49M |
|
| Cash Flow Statement Financials | |
$-112.54M |
|
$94.35M |
|
$155.07M |
|
$31.79M |
|
$167.94M |
|
$136.15M |
|
|
Stock-Based Compensation |
$8.65M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.44 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-112.96M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-33.43% |
|
-33.43% |
|
-17.58% |
|
-33.43% |
|
$2.93 |
|
$-2.15 |
|
$-2.14 |
|